Comparative Pharmacology
Head-to-head clinical analysis: FACTIVE versus IQUIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTIVE versus IQUIX.
FACTIVE vs IQUIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
DNA gyrase inhibitor; topoisomerase IV inhibitor; bactericidal against Gram-positive and Gram-negative bacteria by blocking DNA replication.
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
1-2 drops of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for up to 5 days total.
None Documented
None Documented
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Terminal elimination half-life is approximately 4-6 hours. This short half-life supports twice-daily dosing in clinical practice (for ophthalmic suspension).
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Primarily renal excretion of unchanged drug (approximately 70-80%). A smaller fraction is excreted as metabolites via the kidneys. Biliary/fecal elimination accounts for less than 10% of the dose.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic